Following a complete response letter last year, Satsuma Pharmaceuticals Inc. received U.S. FDA approval of dihydroergotamine nasal powder to treat acute migraine with or without aura. Branded Atzumi, ...

The FDA has granted marketing authorization to CT-132 for the preventive treatment of episodic migraine in patients aged 18 years and older.

The FDA has approved Atzumi (dihydroergotamine) nasal powder for the acute treatment of migraine with or without aura in adults.

The FDA has issued a Complete Response Letter to Telix Pharmaceuticals regarding the NDA for TLX101-CDx for the imaging of gliomas.

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to recent findings by rare cancer researcher Dr. Taran Gujral, head of Fred Hutch's ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

According to the American Migraine Foundation, people with migraine who are at a healthy weight have about a 3 percent chance of developing chronic headaches in a year. The combination of migraine ...

Headaches are a common yet disruptive ailment, ranging from mild discomfort to severe pain. With various types, each with distinct triggers and symptoms, it is essential to understand your ...

For people suffering from migraines, finding effective treatments extends beyond medication to examining dietary influences. While cheese has traditionally been considered a migraine trigger ...

A Pennsylvania man is suing America PAC, a political group linked to Elon Musk, alleging unpaid wages for collecting voter petition signatures during the 2024 election campaign. He claims the PAC ...

Cameron Munster admits his State of Origin return for Queensland is no guarantee as he put forward his candidacy as a possible bench utility option.